In a 67‑year‑old woman with an ECG showing marked sinus bradycardia, fusion beats, and ventricular escape complexes, what is the significance of these findings and is prescribing lisdexamfetamine (Vyvanse) for binge‑eating disorder advisable?

Prescribing Vyvanse in a 67-Year-Old Woman with Marked Sinus Bradycardia and Ventricular Escape Complexes

Vyvanse (lisdexamfetamine) should NOT be prescribed to this patient due to her significant cardiac conduction abnormalities, which represent a direct contraindication to stimulant therapy.

Understanding the EKG Findings

This patient's electrocardiogram demonstrates severe conduction system disease with three critical features:

• Marked sinus bradycardia: The sinus node is firing at an abnormally slow rate
• Ventricular escape complexes: The ventricles are generating their own backup rhythm because the normal conduction system is failing
• Fusion complexes: These occur when a sinus impulse and ventricular escape beat depolarize the ventricles simultaneously, indicating complete or high-grade atrioventricular block 1

This constellation of findings indicates advanced conduction system disease requiring urgent cardiology evaluation and likely permanent pacemaker placement 2, 1. The presence of ventricular escape rhythm suggests the patient is dependent on a ventricular pacemaker for maintaining cardiac output, which places her at high risk for sudden cardiac death 3.

Why Vyvanse is Contraindicated

Direct FDA Contraindications

The FDA label for Vyvanse explicitly states: "Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease" 4.

Advanced conduction system disease with ventricular escape rhythm qualifies as "serious cardiac disease" and represents an absolute contraindication.

Cardiovascular Effects of Lisdexamfetamine

Vyvanse causes predictable cardiovascular stimulation:

• Increases heart rate by 2.8-5.2 beats per minute in a dose-dependent manner 5
• Elevates blood pressure and pulse requiring regular monitoring 4
• Can precipitate serious arrhythmias in patients with underlying cardiac disease 4

In a patient with failing conduction tissue and dependence on ventricular escape rhythm, the sympathomimetic effects of lisdexamfetamine could:

1. Suppress the ventricular escape pacemaker
2. Precipitate life-threatening bradycardia or asystole
3. Trigger ventricular arrhythmias

Risk of Sudden Death

The FDA boxed warning specifically addresses this: "Sudden death has happened in people who have heart defects or other serious heart disease" 4. Advanced AV block with ventricular escape rhythm represents exactly this type of serious cardiac disease.

Immediate Management Priorities

Cardiac Evaluation Takes Precedence

Before considering ANY treatment for binge eating disorder, this patient requires:

1. Urgent cardiology consultation for evaluation of symptomatic bradycardia 1
2. Assessment for permanent pacemaker placement: Her EKG findings (complete heart block with ventricular escape) are a Class I indication for permanent pacing 2, 1
3. Evaluation for underlying cardiac disease: Complete heart block in a 67-year-old woman may indicate ischemic heart disease, infiltrative cardiomyopathy, or degenerative conduction system disease 1

Alternative Treatments for Binge Eating Disorder

Once cardiac stability is achieved (likely after pacemaker placement), consider these FDA-approved and guideline-recommended alternatives:

First-line psychotherapy (safest option):

• Eating disorder-focused cognitive-behavioral therapy is the APA's primary recommendation for binge eating disorder 6
• Interpersonal therapy in individual or group formats 6

Pharmacotherapy alternatives (after cardiac stabilization):

• Topiramate: Effective for reducing binge episodes and weight loss, with no significant cardiac effects 7, 8
• SSRIs: While less effective than lisdexamfetamine, they lack the cardiovascular risks 6
• Naltrexone/bupropion: Though evidence is weaker, it avoids stimulant-related cardiac risks 8

The 2025 Circulation Research guideline confirms that lisdexamfetamine is first-line FDA-approved medication for binge eating disorder 9, but this recommendation applies to patients without serious cardiac contraindications.

Clinical Pitfalls to Avoid

1. Do not assume bradycardia is benign in older adults: Ventricular escape rhythm indicates life-threatening conduction disease 1

2. Do not prescribe stimulants without cardiac clearance: Even in younger patients, baseline ECG is recommended before stimulant therapy 6

3. Do not delay cardiac evaluation: This patient's rhythm abnormalities require urgent assessment regardless of binge eating disorder treatment 1

4. Do not use "cardiac monitoring" as justification for prescribing: The FDA contraindication is absolute for serious cardiac disease—monitoring does not mitigate the risk 4

Summary Algorithm

Step 1: Recognize EKG findings indicate serious cardiac disease (complete AV block with ventricular escape)

Step 2: Refer urgently to cardiology for pacemaker evaluation

Step 3: After cardiac stabilization with pacemaker (if indicated), initiate psychotherapy for binge eating disorder

Step 4: If pharmacotherapy needed after cardiac stabilization, consider topiramate or SSRIs—NOT lisdexamfetamine

The presence of advanced conduction system disease with ventricular escape rhythm makes lisdexamfetamine absolutely contraindicated, regardless of the severity of binge eating disorder 4.